Stay informed with free updates
Simply sign up to the Film myFT Digest — delivered directly to your inbox.
Based on a novel by Ruth Ware, queen of lifestyle whodunits, The Woman in Cabin 10 could have been called The Strange Case of the Missing…
SEOUL/SANTA CLARA, CALIF., October 10, 2025 – Hyundai Motor Company and PlusAI’s autonomous XCIENT Fuel Cell Class 8 heavy-duty truck has been named one of TIME’s ‘Best Inventions of 2025’.
For over two decades, TIME has published its annual Best Inventions list, spotlighting innovations that transform how we live, work and move. This year’s selection of 300 groundbreaking solutions highlights the industry-defining potential of Hyundai Motor and PlusAI’s hydrogen-powered autonomous truck.
The award-winning truck integrates Hyundai Motor’s proven XCIENT Fuel Cell Class 8 heavy-duty truck platform — the world’s first mass-produced hydrogen-powered heavy-duty truck — with PlusAI’s Level 4 autonomous SuperDrive™ virtual driver. The combination delivers a cutting-edge solution for long-haul freight, enabling zero-tailpipe-emission operations and enhanced logistics efficiency.
“This recognition by TIME is a testament to the power of innovation and collaboration,” said Chul Youn Park, Senior Vice President and Head of Global Commercial Vehicle and Light Commercial Vehicle Business Division at Hyundai Motor Company. “It’s a true honor to be recognized by TIME’s Best Inventions, which celebrates innovations that shape a better future. At Hyundai, we aim to contribute to building a sustainable and safe freight ecosystem through hydrogen-powered commercial vehicles. We deeply value our partnership with PlusAI, which has been instrumental in realizing this shared vision.”
David Liu, CEO and Co-founder at PlusAI, added, “It is an honor to have TIME recognize our collaboration with Hyundai Motor as one of the Best Inventions of 2025. This award underscores PlusAI’s leadership as an AI-native technology company, where our autonomous driving system is designed from the ground up to deliver innovation with safety and scalability at its core. By combining Hyundai’s hydrogen fuel cell platform with our cutting-edge autonomous driving software, we are setting a new benchmark for sustainable and transformative freight transportation.”
INCHEON, South Korea, Oct. 9, 2025 /PRNewswire/ — Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).[1]
Aflibercept is a VEGF inhibitor formulated as an injection for the eye that blocks the growth of new blood vessels and decreases the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor (PlGF), two growth factors involved in ocular angiogenesis.
“Timely access to effective therapies is essential for individuals affected by retinal diseases. We are proud to have EYDENZELT approved by the FDA, and we look forward to expanding the availability and access of biological treatments across the U.S.,” said Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. “With EYDENZELT demonstrating biosimilarity to its reference product, we believe this approval will mark a significant milestone in the treatment landscape of retinal diseases—helping physicians broaden their options and improving patient outcomes.”
The FDA approval was based on a totality of evidence including analytical, nonclinical, and clinical data. In a randomized, double-masked, parallel-group, multicenter phase III study of EYDENZELT, the efficacy, safety, pharmacokinetics, and immunogenicity of EYDENZELT was compared to EYLEA in patients with diabetic macular edema (DME). The 52-week trial included 348 patients with DME. The primary endpoint was the change in best corrected visual acuity measured at week 8 from baseline, comparing EYDENZELT and EYLEA. Results of the study showed that EYDENZELT met the predefined equivalence criteria, and secondary endpoints of efficacy, safety, and immunogenicity also showed trends similar to EYLEA.
“Advanced age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment in the world and nearly 20 million people in the U.S. are living with some form of age-related macular degeneration,” said Dr. David M. Brown, Director, Retina Consultants of Texas Research Centers, Co-chair, Medical Leadership Board Retina Consultants of America. “EYDENZELT will be an important new addition to our options for the treatment of our patients with serious retinal diseases.”
EYDENZELT is Celltrion’s first FDA-approved biologic product in ophthalmology. EYDENZELT was also approved by the European Commission (EC) in February 2025.
###
About EYDENZELT® ( aflibercept-boav )
EYDENZELT® (aflibercept-boav) is a vascular endothelial growth factor (VEGF) inhibitor referencing EYLEA® (aflibercept). EYDENZELT is approved based on a comprehensive data confirming the therapeutic equivalence EYLEA. In the U.S., EYDENZELT is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).
INDICATIONS
EYDENZELT® (aflibercept-boav) is indicated for the treatment of patients with:
IMPORTANT SAFETY INFORMATION
For more information, see Full Prescribing Information .
About Celltrion , Inc.
Celltrion, Inc. is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.
About Celltrion USA
Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has ten biosimilar products approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media: LinkedIn.
FORWARD-LOOKING STATEMENT
Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.
These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.
In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries’ management, of which many are beyond its control.
Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.
Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.
Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.
Trademarks
EYDENZELT® is a registered trademark of Celltrion, Inc.
EYLEA® is a registered trademark of Regeneron Pharmaceuticals Inc.
References
[1] EYDENZELT U.S. prescribing information (2025)
US–24-00028
For further information please contact:
Katie Gallagher
[email protected]
+1 617-657-1324
SOURCE Celltrion
What is Fonterra’s Foodservice business?
Foodservice is the business of preparing and serving food and beverages outside the home. It includes a wide range of settings such as restaurants, bakeries, beverage outlets, cafeterias, and quick-service restaurants.
Fonterra’s foodservice brand, Anchor Food Professionals, supplies high-performing dairy products to customers in more than 50 countries. We work closely with these customers to help them meet the needs of their consumers by offering innovative dairy products and solutions that align with current food trends.
Our Foodservice business focuses on five key channels: bakery, beverage, dining, quick-service restaurants, and retailised foodservice, which includes supermarkets, convenience stores, and packaged snacks.
Thomas Tuchel may have expressed public displeasure with England’s fans after the emphatic Wembley win against Wales, but the performance of his players will have left him feeling only the warm glow of vindication.
Tuchel delivered a…
On the touchline, Clarke had words with his assistant Steven Naismith.
“How are we level, Naisy?” asked Clarke.
“No idea, gaffer,” replied Naismith.
“It’s a miracle, Naisy,” said the manager,
“Give us six numbers for the lotto, boss,” said Naismith.
Continue Reading
The Netherlands’ ZEZ-Fs evolved from voluntary collaboration between local authorities and the private sector to test zero-emission urban freight solutions in regional pilots. By 2019, key targets from these collaborations were embedded in national legislation that committed 30–40 larger municipalities to establish ZEZ-Fs by 2025. Subsequent legislation established that zones must be announced at least 4 years in advance, helping to ensure that freight operators have sufficient time to prepare.
Alongside the flexibilities described above, the national government and local authorities have introduced a range of measures to prepare local publics for the ZEZ-F rollout. These include:
Subsidies, like the national Subsidy Scheme for Emission-Free Commercial Vehicles, which offered up to €5,000 per battery electric van between 2021 to 2024, and the Purchase Subsidy for Zero-Emission Trucks, which offers up to €115,200 for buying or leasing N2 or N3 trucks.
Tax incentives that exempt zero-emission vans from the one-time registration tax of €74.41 per gram CO2/km introduced in 2025, when the previous registration tax exemption for all new commercial vans was removed.
Support for charging infrastructure deployment, such as the Public Charging Infrastructure Heavy Transport Subsidy Scheme, which offers a subsidy of at least €25,000 for the deployment of public fast charging infrastructure.
Category B licenses for heavy zero-emission vans: A category B license allows the operation of vehicles with a gross vehicle weight of up to 3.5 tonnes. To account for the added weight of BEVs, an EU exemption allows drivers with a standard B license to operate zero-emission vans up to 4.25 tonnes. This exemption was introduced as part of a pilot program in the Netherlands and was originally set to expire in 2024, but has been extended pending a new EU driving license directive.
While not exhaustive, these measures have contributed to the adoption of zero-emission vans and trucks and to the broader framework supporting the ZEZ-Fs rollout.
Lessons for other countries
The Dutch experience offers insights for other governments considering ZEZ-Fs.
Starting with voluntary collaboration allows governments to build trust and test solutions before regulation. Real-world pilots enabled scalable testing before regulations kicked in, building trust and minimizing disruption while seeding the legal frameworks and stakeholder commitment that made implementation successful.
Providing adequate lead times and financial support to ease transitions is critical. Adequate lead times, alongside purchase subsidies, technical guidance, and support for infrastructure rollout, have helped accelerate the Netherlands’ fleet transition. Early investment in one of Europe’s densest charging infrastructure networks, plus financial support, gave businesses the confidence and means to shift.
Combining national rules with local flexibility can help meet diverse urban needs. By allowing cities to tailor ZEZ boundaries and complementary measures within a consistent national framework, the Netherlands has avoided policy fragmentation while also respecting cities’ diverse logistical needs. This approach also benefits businesses operating across multiple cities by providing clear, uniform regulations that enable straightforward, long-term planning. In turn, this predictability helps manufacturers and suppliers to better align their production and development efforts to meet the growing demand for BEVs.
Prioritizing gradual implementation with clear, fixed deadlines can help balance policy ambition with business realities. The transitional periods for different vehicle categories in the Netherlands has balanced environmental objectives with practical business realities, providing adjustment time while advancing toward zero-emission requirements.
The Netherlands shows how strong policy frameworks—combining clear regulations with support measures—can accelerate the shift to zero-emission commercial vehicles. Its collaborative, bottom-up approach has laid the foundation for broader urban logistics transformation. As cities pursue climate and air quality goals, the Dutch model offers a proven path to scale zero-emission freight while easing the transition for businesses.
Though the new animated feature “Aztec Batman: Clash of Empires” bears the name of one the most emblematic American superheroes, its creation was entirely a Mexican affair.
The action-packed saga reimagines the caped crusader as a young Aztec…
